Compass Pathways Stock Surges 40% Following White House Executive Order on Psychedelic Therapies
Compass Pathways (CMPS) stock surged over 40% after a White House Executive Order aimed at accelerating psychedelic drug approvals. The company reported positive phase 3 trial results for its synthetic psilocybin treatment, COMP360, for treatment-resistant depression. The order is expected to expedite the approval process for such therapies.
Tickers: $CMPS
Topics: biotechnology Compass Pathways mental health psilocybin therapy regulatory changes